Subject: Carrington Studying A New AIDS Drug During 6-Month Trial
Date: Published: 10/21/87 37 lines
Source:  WALL STREET JOURNAL. Copyright Dow Jones & Co. Inc. 

    Carrington Studying
    A New AIDS Drug
    During 6-Month Trial

    DALLAS -- Carrington Laboratories Inc. said it and
 Innogenetics N. V. of Gent, Belgium, have begun a six-month
 clinical trial to evaluate the effectiveness of a new drug
 against acquired immune deficiency syndrome.
    The controlled study -- conducted on 48 patients with
 AIDS-related complex -- also will determine whether
 Carrington's Carrisyn drug and AZT, an antiviral drug
 approved for the treatment of AIDS, act synergistically when
 used together.
    Carrington said the trial will include a research program
 at Innogenetics, a biotechnology concern, to examine
 Carrisyn's immune stimulation.  The drug has been shown to
 stimulate the cells that regulate the body's immune system,
 Carrington said.
    Innogenetics's affiliate, Barc N. V., will monitor the
 trial in cooperation with clinicians and researchers in six
 university hospitals in Europe, Carrington said.
    Carrington said the studies are intended to produce data
 to support an application to market Carrisyn in some European
 and African countries.
    Carrington manufactures and markets wound-healing,
 skin-care and other products, and conducts research to
 develop new pharmaceuticals.

[This article is made available here by Dow Jones Co. for the 
personal and non-commercial use of callers to this bbs, in the 
hope that it will be of some help to those who are suffering 
from the disease and others who are seeking to help them.]